TY  - BOOK
AU  - Narkhede, Mayur
AU  - Sarraf Yazdy, Maryam
TI  - Determining the sequence of novel therapies in the treatment of relapsed Hodgkin's lymphoma
SN  - 1747-4094
PY  - 2018///
KW  - *Antineoplastic Combined Chemotherapy Protocols/tu [Therapeutic Use]
KW  - *Hodgkin Disease/dt [Drug Therapy]
KW  - Bleomycin/tu [Therapeutic Use]
KW  - Dacarbazine/tu [Therapeutic Use]
KW  - Doxorubicin/tu [Therapeutic Use]
KW  - Female
KW  - Hodgkin Disease/ep [Epidemiology]
KW  - Humans
KW  - Immunoconjugates/tu [Therapeutic Use]
KW  - Male
KW  - Recurrence
KW  - United States/ep [Epidemiology]
KW  - Vinblastine/tu [Therapeutic Use]
KW  - MedStar Washington Hospital Center
KW  - Hematology and Oncology
KW  - Journal Article
N2  - INTRODUCTION: Hodgkin lymphoma (HL) accounts for about 10% of all lymphomas in the United States. Exceptional progress has been made in the treatment of HL with complete response rates up to 94% in limited stage and 88% in advanced stage disease with regimens such as adriamycin, bleomycin, vinblastine, dacarbazine in the frontline setting. Nevertheless, up to 10% of patients with limited stage disease and 20-30% of those with advanced stage HL relapse. In the last decade, newer agents such as brentuximab vedotin (BV) and checkpoint inhibitors have been approved by the FDA for treatment of patients with relapsed or refractory HL. As these newer agents are increasingly incorporated in both the front-line and relapsed settings, their optimal sequence becomes challenging for clinicians. Areas covered: This review will discuss the evidence behind the approval of BV and checkpoint inhibitors in HL and the appropriate sequence for using them in relapsed Hodgkin lymphoma. Expert Commentary: The appropriate sequence of BV and/or checkpoint inhibitors in the relapsed setting depends on the regimen used in the frontline setting
UR  - https://dx.doi.org/10.1080/17474086.2018.1516135
ER  -